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Neonatal intensive care has advanced rapidly in the last 40 years, with dramatic decreases
in mortality and morbidity; however, for neonatal seizures, neither therapies nor outcomes
have changed significantly. Basic and clinical studies indicate that seizures in neonates
have long-term neurodevelopmental and psychiatric consequences, highlighting the need
for novel pharmacotherapeutics. First-line treatments targeting GABAA receptors, like bar-
biturates and benzodiazepines, are limited in their efficacy and carry significant risks to the
developing brain. Here, we review the use of current GABA agonist therapies for neona-
tal seizures and suggest other treatment strategies given recent developments in the
understanding of disease pathogenesis. One promising avenue is the indirect manipula-
tion of the GABAergic system, via the modulation of neuronal Cl− gradients, by targeting
the cation-Cl− cotransporters (NKCC1 and KCC2) or their regulatory signaling molecules.
This strategy might yield a novel class of more efficacious anti-epileptics with fewer side
effects by specifically addressing disease pathophysiology. Moreover, this strategy may
have ramifications for other adult seizure syndromes in which GABA receptor-mediated
depolarizations play a pathogenic role, such as temporal lobe epilepsy.
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CURRENT GABA AGONISTS AND PRODRUGS
(BENZODIAZEPINES AND BARBITURATES) ARE
INADEQUATE IN THE TREATMENT OF NEONATAL SEIZURES
Seizures are the most common neurological emergency in the
neonate, with an estimated prevalence of 1.8–5 seizures/1000 live
births in the US (Jensen, 2009). In fact, the lifespan risk of seizures
is highest in the neonatal period. There are many conditions
that may cause neonatal seizures, the most common of which
is hypoxia/ischemia (Ronen et al., 1999; Tekgul et al., 2006) caus-
ing white matter injury (Figure 1). Seizures in the newborn can
cause permanent and severe cognitive and behavioral abnormali-
ties, as well as enhanced epileptogenicity later in life (Baram, 2003;
Holmes, 2004; Swann, 2005), underlining the importance of effec-
tive therapy. Although neonatal seizures have a different etiology
than adult seizures, current standard therapy involves compounds
whose efficacy has only been well established in older patients.
Benzodiazepines and barbiturates are the most common first-line
therapies for neonatal seizures; however, the efficacy of these drugs
in treating seizures in the newborn is not supported by robust evi-
dence. The use of these drugs may have significant short- and
long-term effects on brain development.
Current therapy for neonatal seizures is usually focused on early
treatment with benzodiazepines and barbiturates. These drugs
generally exert their effects via modulation of GABA action at the
GABAA receptor, or by antagonism of NMDA receptors. Although
these drugs are effective in adults, they do not control neonatal
seizures well. When given as monotherapy, phenobarbital controls
seizures in less than half of newborns (Painter et al., 1999). In a
study examining six neonates treated with second-line benzodi-
azepines, none responded to this medication (Boylan et al., 2004).
A Cochrane review concluded that there was little evidence from
the literature that supported the use of these drugs in treating
neonatal seizures (Booth and Evans, 2004). Furthermore, some
have suggested that benzodiazepines and barbiturates may resolve
the outward clinical symptoms of seizures due to sedation with-
out correcting underlying abnormal brain activity, exacerbating
“electroclinical dissociation” between clinical symptoms and elec-
trographic recording and leading to an overestimation of the true
efficacy of these drugs (Boylan et al., 2002).
Developmental changes in the expression and activity of neuro-
transmitters and their receptors provide some insight into the basis
of the increased susceptibility of the neonatal brain to seizures and
the relative inefficacy of benzodiazepines and barbiturates in con-
trolling them. Developmentally regulated ion channel configura-
tions that facilitate easier depolarization and an increased reliance
on glutamatergic transmission together increase the excitability
of the neonatal brain, putatively to promote synaptogenesis, but
simultaneously conferring a disposition to seizures (Rakhade and
Jensen, 2009). Differences in GABA signaling in the immature
brain also contribute to its overall enhanced excitability. GABA
is the major inhibitory neurotransmitter in the adult central ner-
vous system, but its receptors and synthetic enzyme do not reach
maximal levels of expression until the fourth postnatal week in rats
(Swann et al., 1989; Brooks-Kayal et al., 2001). Furthermore, while
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FIGURE 1 | Magnetic resonance imaging (MRI) of neonatal
hypoxic-ischemia. Neonatal hypoxic-ischemia is a common cause of white
matter injury, the underlying factor in the development of neonatal seizures.
These manifest on MRI as either punctate white matter lesions (red circles;
seen on T1-weighted MRI imaging) or diffuse excessive high signal intensity
(white square; seen on T2-weighted MRI imaging). Reprinted from
Wisnowski et al. (2013) under the terms of the Creative Commons
Attribution License.
GABA hyperpolarizes adult neurons, it can depolarize neonatal
neurons in vivo (Loturco et al., 1995). This may explain why benzo-
diazepines and barbiturates, which are GABAA receptor agonists,
have limited efficacy in controlling neonatal seizures.
SHORT-TERM SIDE EFFECTS OF BENZODIAZEPINES AND
BARBITURATES
In addition to limited efficacy, a growing body of evidence suggests
that benzodiazepines and barbiturates cause short- and long-term
harm to the developing neonatal brain. Cellular and neuromor-
phological effects of antiepileptic drugs have thus far only been
extensively studied in rodent models, so further study is required
to determine the acute neurotoxic effects of these drugs in humans.
In the neonatal rat, administration of any of the common
antiepileptic drugs – phenytoin, phenobarbital, diazepam, clon-
azepam, vigabatrin, or valproate – all caused apoptotic neurode-
generation that was associated with reduced expression of neu-
rotrophins (Bittigau et al., 2002). Importantly, these detrimental
effects are consequences of the mechanism of action of these drugs
and not cross-reactivity, pharmacokinetics, or other compound-
specific toxicities. For example, apoptotic neurodegeneration is
seen in phenobarbital and diazepam, but also in other anesthet-
ics that agonize the GABAA receptor (Jevtovic-Todorovic et al.,
2003). Observations of apoptosis following anesthetics that ago-
nize GABAARs have also been reported in non-human primates,
suggesting a similar effect in humans. For example, isofluorane,
whose mechanism of action includes activation of GABAARs,
induces neuro-apoptosis in neonatal rhesus macaques (Brambrink
et al., 2010, 2012).
The two most common classes of anti-convulsant drugs are
GABAA receptor agonists and NMDA receptor antagonists. Both
NMDA receptor antagonists (Haberny et al., 2002; Hansen et al.,
2004) and GABAA receptor agonists (Bittigau et al., 2002) cause
the activation of apoptotic pathways and down-regulate neu-
rotrophins, which together cause apoptotic neurodegeneration
and inhibit neurogenesis, particularly in regions of substan-
tial neural growth in the early postnatal period such as the
sub-ventricular zone of lateral ventricles, cerebellum, and the
subgranular zone of the hippocampal dentate gyrus. Anticonvul-
sants that antagonize NMDA receptors or agonize GABAA recep-
tors cause significant changes in the neonatal rat cerebral cortex
proteome as soon as 1 day following therapy, including deregula-
tion of proteins associated with apoptosis, oxidative stress, inflam-
mation, proliferation, and potentiation, suggesting a multitude of
mechanisms by which such early exposure may result in neurode-
generation (Kaindl et al., 2008). Barbiturates may also alter the
development of synaptic junctions (Dydyk and Rutczynski, 1980).
The adverse effects of antiepileptic drugs are age-dependent.
The rodent brain undergoes a period of increased synaptoge-
nesis, glial cell multiplication, myelination, and brain network
reorganization in the first three postnatal weeks (Dobbing, 1974),
during which the neonatal rat is most susceptible to developmental
toxicity from antiepileptic drugs (Kaindl et al., 2008). The corre-
sponding brain growth in humans begins during pregnancy and
lasts up to the third postnatal year (Dobbing, 1974; Herschkowitz,
1988), also suggesting enhanced susceptibility to toxicity during
this period.
The changes in cell proliferation and survival signaling path-
ways induced by common antiepileptic drugs likely contribute to
altered brain morphology that is observed soon after develop-
mental exposure (Figure 2). Decreased gray matter volume and
altered gray matter morphology in a number of brain regions fol-
lowing developmental exposure to antiepileptic drugs is seen in
rodents (Ikonomidou et al., 2007). Early barbiturate administra-
tion is consistently associated with decreased brain weight (Schain
and Watanabe,1975; Diaz et al., 1977) and neuronal number (Yanai
et al., 1979) throughout rodent life, which is likely related to both
apoptotic neurodegeneration and inhibited neurogenesis.
LONG-TERM SIDE EFFECTS OF BENZODIAZEPINES AND
BARBITURATES
Determination of long-term cognitive and behavioral effects of
early treatment with common anticonvulsants is difficult because
cognition, behavior, and neuromorphology later in life is fre-
quently heavily confounded by the condition for which anti-
convulsant therapy was initially prescribed. However, there is gen-
eral consensus that neonatal therapy with agents that interfere with
GABA or glutamate transmission, including benzodiazepines, bar-
biturates, and phenytoin, cause cognitive and behavioral defects
later in life. These cognitive and behavioral defects have been
reported in both animal models and in humans.
Cognitive and behavioral deficits are likely caused by apop-
totic neurodegeneration and inhibited neurogenesis in prolif-
erative cells in the immature brain, and by changes in neural
organization caused by the death of these neurons. Short-term
drug-induced inhibition of neurogenesis can indirectly lead to
destruction of pre-formed nerve populations and can thereby have
a much broader impact on morphology later in development.
For example, neonatal administration of phenobarbital led to a
destruction of cerebellar and hippocampal granule cells, which
form early in the postnatal period, as well as cerebellar Purkinje
and hippocampal pyramidal neurons, which are formed prena-
tally, before phenobarbital was administered (Yanai et al., 1981).
Since prenatally formed nerve cell populations are culled during
synaptogenesis in normal brain development,barbiturate-induced
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FIGURE 2 | GABA agonists affect the development of the neonatal brain.
Muscimol, a potent selective agonist for the GABAA receptor, was
administered to neonatal rats on postnatal days 0 and 1, and histologic
specimens were obtained on postnatal day 21. Representative
photomicrographs illustrate neuronal nuclear antigen-immunoreactive
neurons in the CA1 region of the hippocampus in (A) sham males, (B)
males+muscimol, (C) sham females, and (D) females+muscimol. Musciol
treated rats have fewer neurons in the CA1 region of the hippocampus than
their sham counterparts. Scale bar=100µm. Reprinted from Nunez et al.
(2003), with permission from Elsevier.
destruction of presynaptic cells that ordinarily mature in the post-
natal period can lead to a reduction in the number of prenatally
formed postsynaptic neurons even without direct toxicity to these
cells, since these pre-formed populations rely on synaptogene-
sis for survival through culling during development (Fishman
and Yanai, 1983). In this way, even minor neurodegeneration or
modulation of synaptogenesis during critical neurodevelopmen-
tal periods in the neonate can have major long-term effects on
network organization and cognitive and behavioral deficits.
There is a wide array of reported cognitive and behavioral
changes that are associated with early anticonvulsive therapy.
Rats receiving phenobarbital show increased agitation, activity
level, and aggression (Diaz and Schain, 1978). Adult rats that
received early barbiturate therapy perform worse in cognitive
tasks aimed at assessing hippocampal function (Yanai et al., 1989).
Exposure to phenobarbital, phenytoin, or lamotrigine during the
second postnatal week resulted in adult deficits in spatial learn-
ing, sensorimotor gating, and other behaviors in rats (Forcelli
et al., 2012). The benzodiazepine diazepam has been shown to
interfere with learning and memory in rats (Pereira et al., 1989;
Holley et al., 1995). One study found that although phenobar-
bital therapy did reduce the number of seizures in developing
rats, the cognitive deficits that resulted from phenobarbital ther-
apy were greater in severity than the deficits in rats that did not
receive phenobarbital, despite the fact that the latter group suffered
more seizures (Mikati et al., 1994). Phenytoin therapy altered
schedule-controlled behavior in rats that outlasted the therapy
itself (Krafft et al., 1982).
Human studies also describe similar cognitive deficits. Chil-
dren aged between 6 months to 3 years who were placed on 1 year
of phenobarbital therapy after suffering from febrile seizures
showed a negative correlation between serum levels of pheno-
barbital and memory concentration subscore of the Binet IQ
test, although no significant difference in overall IQ or parent-
reported behavior compared to controls was reported at 8 or
12 months of follow-up (Camfield et al., 1979). In a much larger
study of 217 children aged between 8 and 36 months with febrile
seizures, phenobarbital use significantly lowered IQ after 2 years
compared to controls, but was not associated with a significant
reduction in seizure recurrence (Farwell et al., 1990). Upon testing
3–5 years after medication had been stopped, early phenobarbi-
tal use significantly lowered performance in language/verbal tests
and was associated with a reduction in IQ (Sulzbacher et al.,
1999).
NOVEL TARGETS OF THE GABAergic SYSTEM: TARGETING
MOLECULES THAT ESTABLISH Cl− GRADIENTS
In the adult nervous system, due to low intracellular levels of Cl−,
GABA inhibits most neurons by activation of GABAARs, causing
Cl− influx, membrane hyperpolarization, and inhibition. Addi-
tionally, GABAAR activation can also inhibit neurons via“shunting
inhibition” by decreasing membrane resistance, which decreases
the efficacy of excitatory signals to reach the critical threshold of
action potential generation (Farrant and Kaila, 2007). Under sev-
eral normal or pathophysiological circumstances, however, GABA
can depolarize and even excite neurons rather than inhibit them.
For example, in immature neurons during development and in
certain neural subpopulations in pathophysiological states, GABA
triggers depolarizations, and potential excitation (Cherubini et al.,
1991; Ben-Ari et al., 1994), for review see (Marty and Llano, 2005).
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FIGURE 3 |WNK3 has opposite effects on NKCC1 and KCC2. Xenopus
oocytes were injected with cRNAs encoding NKCC1 (A) or KCC2 (B)
alone and in combination with wild-type or kinase-dead mutant WNK3.
86Rb+ influx through NKCC1 (A) or efflux through KCC2 (B) was
determined as a measure of flux through these cation Cl-channels. (A)
WNK3 activates NKCC1. NKCC1 normally shows little activity under
hypotonic conditions (180 mosM) and is active in isotonic conditions
(200 mM). WNK3 increases NKCC1 to maximal activity in both
conditions. Kinase-dead WNK3 strongly inhibits NKCC1 activity,
indicating phosphorylation of NKCC1 by WNK3 is necessary for activity.
*, P <0.0001 vs. NKCC1 alone. (B)WNK3 inactivates KCC2. KCC2 is
partially active under isotonic conditions and active under hypotonic
conditions. WNK3 inhibits KCC2 under both conditions. Kinase-dead
WNK3 strongly activates KCC2 under both hypotonic and isotonic
conditions. *, P <0.0001 vs. KCC2 alone. Taken together, these data
suggest that WNK3 is an important regulator of NKCC1 and KCC2
activity. Its kinase activity activates NKCC1 and inhibits KCC2. Figure
represents data from Kahle et al. (2005).
Although some have suggested that the observation of excitatory
GABA responses is experimental artifact resulting from cellular
damage in ex vivo studies (Bregestovski and Bernard, 2012), a large
and growing body of evidence has confirmed excitatory GABA
signaling in the developing brain in vivo and its physiological
significance during development (Ben-Ari et al., 2012).
The depolarizing effect of GABA results from a change in the
GABAA reversal potential (EGABA) often secondary to an increased
neuronal accumulation of Cl−, though HCO−3 also plays a role.
Several notable ion channels and transporters are integral for neu-
ronal Cl− homeostasis. Among these are the bumetanide-sensitive
Na+-K+-Cl− co-transporter NKCC1, which transports Cl− into
the cell, and KCC2, which normally extrudes it (Kahle et al., 2008b;
Blaesse et al., 2009) (Figure 3).
In immature neurons, the Cl−-exporting activity of KCC2 is
lower than in mature neurons (Rivera et al., 1999), and in the
context of NKCC1 expression, neuronal [Cl−]i is higher and
EGABA is more depolarized (Figure 3B). Moreover, long runs of
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action potentials in single neurons (Woodin et al., 2003), or pro-
longed seizures may result in an activity-dependent accumulation
of intracellular Cl− (Khalilov et al., 2003; Dzhala et al., 2010).
These data might provide insight as to why traditional anti-seizure
medications are less effective when given later in the course of
neonatal seizures (Painter et al., 1999).
Ion transport proteins that establish Cl− gradients across neu-
ronal membranes and contribute to depolarizing GABA responses
in the immature brain could be novel targets for modulation
of the GABAergic system in treating neonatal seizures (Kahle
et al., 2008b). The commonly used loop diuretic bumetanide has
a higher affinity for NKCC1 than KCC2 at low concentrations
(Isenring et al., 1998; Hannaert et al., 2002). In a human neonate
in status epilepticus (Kahle et al., 2009) and in animal models of
status epilepticus (Dzhala et al., 2005), bumetanide reduces electro-
graphic seizures and exhibits synergy with phenobarbital, which
increases the open probability of the GABAA channel (Dzhala et al.,
2008).
While several studies have reported anti-convulsant effects of
bumetanide (Schwartzkroin et al., 1998; Reid et al., 2000; Mazarati
et al., 2009),others have found no significant anti-convulsant effect
(Ostergaard et al., 1972; Mares, 2009; Minlebaev and Khazipov,
2011). Most of the studies that demonstrate efficacy of bumetanide
were performed when it was administered with an anesthetic or
other drug that has GABA-modulatory effects, like phenobarbital.
Other NKCC1 inhibitors with greater blood-brain-barrier pene-
tration may have improved efficacy. Bumetanide pro-drugs that
mask the hydrophilic acid group with esters to facilitate transport
into the brain before releasing the active molecule are currently
being tested (Loscher et al., 2013).
Currently there are two clinical trials evaluating bumetanide as
a treatment for neonatal seizures. A phase I trial (NCT00830531)
is actively enrolling patients in a randomized, double-blind,
controlled dose-escalation study of bumetanide as an add-on
therapy to treat refractory seizures caused by hypoxic-ischemic
encephalopathy. The estimated study completion date is Decem-
ber 2015. A second trial (NCT01434225) is being performed by
a large, multi-center European group in an “open-label,” dose-
escalation fashion to assess the effect of bumetanide in addition
to phenobarbital for the treatment of neonatal seizures caused
by hypoxic-ischemic encephalopathy. Data from these pilot stud-
ies will be utilized to guide the design of larger Phase III trials
that will determine the efficacy of bumetanide in the treatment of
neonatal seizures.
There are some concerns about the modulation of
depolarizing GABA responses based on its importance during
neurodevelopment. Studies suggest the“premature”shift of EGABA
via NKCC1-knockdown or KCC2-overexpression may result in
cortical neurons with fewer and shorter dendrites (Cancedda et al.,
2007), less mature dendritic spines with decreased density and
increased lengths, and fewer glutamatergic inputs received by cor-
tical pyramidal neurons (Wang and Kriegstein, 2008). Some of
these observations have also been recapitulated in rats (Wang and
Kriegstein, 2011). More rigorous, long-term follow-up in neonates
receiving bumetanide therapy is required, including comparison
with current therapies, to determine neuropsychiatric sequelae
associated with modulation of neuronal Cl− gradients in GABA
FIGURE 4 | Inhibition ofWNK3 kinase activity potently reduces
stimulatory phosphorylation of NKCC1. WNK3 regulates the
phosphorylation of NKCC1. Xenopus oocytes were injected with the
indicated cRNAs and incubated at varying extracellular osmolarities (180,
200, and 220 mOsm). After incubation, oocytes were lysed, and Western
blotting was performed with probes for phosphorylated NKCC1 (P-NKCC1)
or unphosphorylated NKCC1 (NKCC1). Phosphorylation of NKCC1 normally
increases from negligible levels in hypotonic conditions (180 mOsm) to
complete phosphorylation in hypertonic conditions (220 mOsm).
Coexpression of NKCC1 with kinase-active WNK3 results in robust
phosphorylation of NKCC1 at all osmolarities, but coexpression with
kinase-dead WNK3 results in marked reduction of NKCC1 phosphorylation
at all osmolarities. Reprinted from Kahle et al. (2005), under their policy that
allows for the use of this figure in this review. Copyright, 2005, The National
Academy of Sciences.
transmission. Nevertheless, in the context of our enhanced under-
standing of the mechanisms of GABA signaling in the neonatal
brain, novel therapies that target Cl− homeostasis are promising
new targets for the treatment of neonatal seizures (Loscher et al.,
2013). Alternative mechanisms to modulate neuronal Cl− home-
ostasis should also be considered. One unexplored mechanism of
Cl− modulation is the manipulation of neuronal Cl− gradients
via targeting of the serine-threonine regulatory kinases of NKCC1
and KCC2 (Kahle et al., 2010). For example, phosphorylation of
NKCC1 at critical N-terminal threonine residues is required for
transporter activity, and this event is catalyzed by the WNK/SPAK
kinase cascade (for review, see Kahle et al., 2008a). Inhibition of
WNK3 kinase activity, a molecule expressed highly in the devel-
oping brain, is the most potent means of concurrently inhibiting
NKCC1 activity and activating KCC2 activity in vitro, and does so
via changes in transporter phosphorylation at critical regulatory
residues (Figure 4) (Kahle et al., 2005; de Los Heros et al., 2006).
Given the coordinated but reciprocal stimulatory and inhibitory
effect of phosphorylation on NKCC1 and KCC2, respectively, we
propose that inhibition of the WNK/SPAK pathway in neurons
might help restore GABA inhibition. These hypotheses are cur-
rently being explored in neuronal culture systems and whole ani-
mal models of seizures in multiple labs, including our own. These
efforts may prove useful not only for neonatal seizure manage-
ment, but also for adult seizure syndromes that exhibit depolarized
GABA responses and altered Cl− homeostasis, such as temporal
lobe epilepsy, in which abnormal expression of Cl− channels also
renders GABA excitatory (Palma et al., 2006; Huberfeld et al., 2007;
Munoz et al., 2007; Brandt et al., 2010; Maa et al., 2011; Miles et al.,
2012; Eftekhari et al., 2013).
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